AFP EXTRA

Code
900.0125
Name
AFP EXTRA
Category
None
Department
Send-Out
Start Date
Expiration Date
Synonyms
Prenatal Risk Triple Marker, Triple Marker
CPT Codes
82105; 82677; 84702
Site
SBMF
Reference Test
30080
ATLAS Test Code

Specimen Information

Type

Gold, SST

Volume

4.0 ml

Transport Info

Refrigerated

Fasting Required?
False
Patient Instructions

Specimen must be collected between 15th and 22nd week of gestation for a complete risk analysis (optimal time is 16-18 weeks)
Collect sample prior to amniocentesis
Complete a Prenatal Risk Information Sheet and send with sample (requires following items of information):
– Estimated due date by LMP
– Mother’s weight in pounds
– Mother’s status of insulin-dependent diabetes
– # of fetuses in current pregnancy (1 or 2)
Note: Pregnancies with more than 2 fetuses cannot be assessed
– Mother’s race
– Mother’s exact date of birth (mm/dd/yyyy)
– Is this a repeat sample? (yes/no)

Reference Range

Neural Tube Defect (NTD) Risk Screen: Negative
Down Syndrome (DS) Risk Screen: Negative

Methodology

Chemiluminescence Immunoassay (CLIA)

Clinical Significance

Used to screen for fetal risk of open Neural Tube Defects (NTD) and Down Syndrome (DS)
This procedure includes performing three (3) tests, alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated/free estriol (uE3), on serum specimens from expectant mothers at the gestational age between 15 and 22 weeks. Based on the results of these tests and maternal age at the expected date of delivery (EDD), risk factors for bearing a child with open neural tube defects (NTD) and/or Down Syndrome (DS) are calculated.

Back

Patients & Visitors

Make a First Appointment Maternity Pre-Registration Make a Donation Recognize a Sarah Bush Lincoln Employee